semaglutide and thyroid medicine hypothyroidism Semaglutide & Thyroid Medication: Safe

Many patients taking GLP-1 medications report nausea and decreased appetite, making intentional hydration a critical part of your treatment plan

But the drug form of GLP-1, known as GLP-1 agonists, can last up to 14 hours in your body

When fluid intake drops, urine becomes concentrated

Whether you are taking any other supplements, such as our GLP-1 Daily Support supplement, to help manage your journey

Patients waiting for insurance approvals or unable to afford $1,000+ monthly medication costs experience continued weight gain and widening metabolic deterioration

Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al